| Returns | 1W : 0.5% , 1M : 11.9%,1Y : 53.6% |
| Peers & Returns | 1W | 1M | 1Y |
| PANACEA BIOTEC LTD | 0.5% | 11.9% | 53.6% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 1.7% | 10.4% | 10.3% |
| DR REDDYS LABORATORIES LTD | 4.9% | -1% | 61.7% |
| DIVIS LABORATORIES LTD | 2.2% | 13.1% | 91.7% |
| CIPLA LTD | -0.3% | -3.5% | 56.4% |
| BIOCON LTD | 1.4% | 4.8% | 51.9% |
| AUROBINDO PHARMA LTD | 4.5% | 12.2% | 88.1% |
| LUPIN LTD | 2.4% | -4.4% | 12.9% |
| TORRENT PHARMACEUTICALS LTD | 0.3% | 2.8% | 37.8% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
-
P/E Calculated based on EPS of
[ Mar2019 - Standalone Results ] -
P/B Calculated based on Book Value of
[ Mar2019 - Standalone Results ] 5.8
P/S Calculated based on Revenues of 209.75 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
NA 185% 104% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2019 2018 2017 Avg_3yrs |
1.65 2.5 2.24 2.13 |
1.85 3.05 2.79 2.56 |
|
[Last Annual Data : Mar2019]
|
||
| Pledged Shares |
69.36 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
54.55% 5274.29% -225.06% -224.63% |
463.39% -160.54% -118.57% -117.77% |
| QtrlyTrend |
-2
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
